Kura Oncology Q1 2024 GAAP EPS $(0.59) Misses $(0.55) Estimate
Portfolio Pulse from Benzinga Newsdesk
Kura Oncology reported Q1 2024 GAAP EPS of $(0.59), missing the consensus estimate of $(0.55) by 7.27%. This represents an 18% increase in losses compared to $(0.50) per share from the same period last year.
May 02, 2024 | 8:19 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Kura Oncology's Q1 2024 earnings report showed a miss on EPS estimates and an increase in losses compared to the previous year.
Missing the EPS estimate and reporting increased losses year-over-year are negative indicators that can lead to a decrease in investor confidence and potentially lower stock prices in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100